REDWOOD CITY, Calif., July 24, 2019 /PRNewswire/ -- Minerva Surgical announced today that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. (the "Federal Circuit") issued its final Mandate, formally ending Hologic's appeal and rejecting Hologic's attempt to reverse its April 2019 decision concluding that Hologic's '183 patent is invalid. On July 16, 2019 the Federal Circuit had already denied Hologic's Petition to reconsider its April decision. Hologic asserted the '183 patent against Minerva in a 2015 lawsuit, after which Minerva successfully challenged the validity of the '183 patent.
Also, based on the Federal Circuit's April decision that the '183 patent is invalid, in May the U.S Federal District Court for the District of Delaware (the "District Court") issued an Order denying Hologic's request to halt sales of Minerva's Endometrial Ablation System based on the '183 patent. In denying Hologic's request, the District Court noted in its Order that: "It is not likely that the Federal Circuit will reconsider its decision or that the Supreme court will grant certiorari." As confirmed today by the Federal Circuit's Mandate, the District Court's prediction that the Federal Circuit was unlikely to reconsider its decision that the '183 patent is invalid proved to be correct. Consequently, Minerva remains free to continue selling its best-in-class Minerva Endometrial Ablation System.
About Minerva Surgical: Minerva Surgical is an innovative medical technology company focused on improving women's health by developing treatments for excessive menstrual bleeding. Minerva and Minerva ES, and associated logos are trademarks and/or registered trademarks of Minerva Surgical in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners.
Important Safety Information: Minerva endometrial ablation is for premenopausal women with heavy periods due to benign causes who are finished childbearing. Pregnancy following the Minerva procedure can be dangerous. The Minerva procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. Minerva endometrial ablation is not a sterilization procedure. Rare but serious risks include, but are not limited to, thermal injury, perforation and infection. Temporary side effects may include cramping, nausea, vomiting, discharge and spotting. For detailed benefit and risk information, please consult the IFU.
For more information on the Minerva procedure and full product labeling, visit: www.MinervaSurgical.com
SOURCE Minerva Surgical